FY2024 Earnings Forecast for Vir Biotechnology, Inc. (NASDAQ:VIR) Issued By HC Wainwright

Vir Biotechnology, Inc. (NASDAQ:VIR) – Stock analysts at HC Wainwright upped their FY2024 earnings per share estimates for shares of Vir Biotechnology in a note issued to investors on Tuesday, May 7th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($3.13) for the year, up from their prior estimate of ($3.43). HC Wainwright currently has a “Buy” rating and a $110.00 price target on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($4.04) per share. HC Wainwright also issued estimates for Vir Biotechnology’s Q1 2025 earnings at ($0.80) EPS, Q2 2025 earnings at ($0.88) EPS, Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($3.10) EPS, FY2026 earnings at ($2.13) EPS, FY2027 earnings at ($1.68) EPS and FY2028 earnings at ($0.61) EPS.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.51. The company had revenue of $56.38 million during the quarter, compared to analysts’ expectations of $11.71 million. Vir Biotechnology had a negative net margin of 677.69% and a negative return on equity of 32.58%. The firm’s revenue was down 10.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.06) EPS.

A number of other research firms have also recently issued reports on VIR. Needham & Company LLC restated a “buy” rating and issued a $15.00 price objective on shares of Vir Biotechnology in a research report on Friday, May 3rd. JPMorgan Chase & Co. boosted their price target on Vir Biotechnology from $10.00 to $12.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.57.

Vir Biotechnology Stock Up 0.2 %

NASDAQ VIR opened at $9.56 on Thursday. The company has a 50-day simple moving average of $9.69 and a two-hundred day simple moving average of $9.64. Vir Biotechnology has a 12-month low of $7.61 and a 12-month high of $27.48. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -2.38 and a beta of 0.47.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Texas Permanent School Fund Corp raised its stake in Vir Biotechnology by 1.4% during the first quarter. Texas Permanent School Fund Corp now owns 74,977 shares of the company’s stock valued at $760,000 after purchasing an additional 1,012 shares in the last quarter. Ballentine Partners LLC lifted its holdings in shares of Vir Biotechnology by 9.2% in the 1st quarter. Ballentine Partners LLC now owns 13,704 shares of the company’s stock valued at $139,000 after acquiring an additional 1,160 shares during the last quarter. Arizona State Retirement System grew its position in Vir Biotechnology by 6.0% in the fourth quarter. Arizona State Retirement System now owns 26,271 shares of the company’s stock worth $264,000 after acquiring an additional 1,476 shares in the last quarter. Fifth Third Bancorp increased its stake in Vir Biotechnology by 69.3% during the third quarter. Fifth Third Bancorp now owns 3,941 shares of the company’s stock worth $37,000 after acquiring an additional 1,613 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in Vir Biotechnology by 96.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,448 shares of the company’s stock worth $32,000 after acquiring an additional 1,692 shares during the last quarter. Institutional investors own 65.32% of the company’s stock.

Insider Transactions at Vir Biotechnology

In other Vir Biotechnology news, CEO Backer Marianne De sold 72,995 shares of Vir Biotechnology stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $9.46, for a total transaction of $690,532.70. Following the sale, the chief executive officer now directly owns 678,457 shares of the company’s stock, valued at approximately $6,418,203.22. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Vir Biotechnology news, EVP Phillip Pang sold 3,321 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $10.24, for a total transaction of $34,007.04. Following the completion of the transaction, the executive vice president now owns 264,679 shares of the company’s stock, valued at $2,710,312.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Backer Marianne De sold 72,995 shares of Vir Biotechnology stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $9.46, for a total transaction of $690,532.70. Following the transaction, the chief executive officer now owns 678,457 shares of the company’s stock, valued at $6,418,203.22. The disclosure for this sale can be found here. In the last ninety days, insiders sold 152,831 shares of company stock valued at $1,525,844. Company insiders own 15.60% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.